Moderna shares spike on hantavirus fears before retreating
Updated
Updated · Barron's · May 7
Moderna shares spike on hantavirus fears before retreating
5 articles · Updated · Barron's · May 7
The move followed a WHO-reported cruise-linked cluster of eight illnesses and three deaths among passengers travelling from Argentina to Cabo Verde.
Five cases were confirmed as hantavirus and three suspected; WHO chief Tedros Adhanom Ghebreyesus said the public health risk remained low despite possible further cases.
Analysts at Evercore ISI said the outbreak offered no meaningful revenue opportunity for Moderna, noting its hantavirus vaccine work with Korea University is early stage and the market is small.
With its hantavirus vaccine trial on hold, what will it take for Moderna to prioritize this deadly but unprofitable disease?
How did a rare rodent-borne virus manage to spread between humans on a modern cruise ship, defying its typical transmission patterns?
As deadly viruses emerge from wildlife, is our market-driven vaccine system prepared for the next, more contagious threat?